ArticleNature communications2024

DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.

Martin Schröder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.